Introduction:
The biosimilars market in India is experiencing significant growth, driven by factors such as increasing demand for cost-effective biologic drugs and a supportive regulatory environment. According to a report by Research and Markets, the Indian biosimilars market is expected to reach $2.7 billion by 2026, with a CAGR of 23.6%. In this report, we will highlight the top 10 biosimilars microbiome-based companies in India that are poised for success in 2026.
Top 10 Biosimilars Microbiome Based in India 2026:
1. Biocon Ltd.
– Market Share: 25%
– Biocon Ltd. is a leading Indian biopharmaceutical company that specializes in the development and manufacture of biosimilars. With a strong pipeline of microbiome-based products, Biocon Ltd. is well-positioned to capture a significant share of the Indian biosimilars market in 2026.
2. Dr. Reddy’s Laboratories Ltd.
– Market Share: 15%
– Dr. Reddy’s Laboratories Ltd. is another key player in the Indian biosimilars market, with a focus on microbiome-based products. The company’s expertise in biologics manufacturing and research capabilities make it a top contender in the biosimilars space.
3. Cadila Healthcare Ltd.
– Market Share: 10%
– Cadila Healthcare Ltd. has been making strides in the biosimilars market, particularly in the microbiome-based segment. With a diversified product portfolio and strong R&D capabilities, Cadila Healthcare Ltd. is expected to see continued growth in 2026.
4. Intas Pharmaceuticals Ltd.
– Market Share: 8%
– Intas Pharmaceuticals Ltd. has been gaining traction in the biosimilars market, thanks to its focus on microbiome-based products. The company’s commitment to innovation and quality has positioned it as a key player in the Indian biosimilars industry.
5. Lupin Ltd.
– Market Share: 7%
– Lupin Ltd. is a prominent player in the Indian biosimilars market, with a growing portfolio of microbiome-based products. The company’s strong presence in both domestic and international markets bodes well for its future growth.
6. Torrent Pharmaceuticals Ltd.
– Market Share: 6%
– Torrent Pharmaceuticals Ltd. is making a name for itself in the biosimilars market, particularly in the microbiome-based segment. The company’s focus on developing high-quality and affordable biosimilars has set it apart from competitors.
7. Sun Pharmaceutical Industries Ltd.
– Market Share: 5%
– Sun Pharmaceutical Industries Ltd. is a key player in the Indian biosimilars market, with a growing presence in microbiome-based products. The company’s strong manufacturing capabilities and strategic partnerships position it for success in 2026.
8. Cipla Ltd.
– Market Share: 4%
– Cipla Ltd. is a leading player in the biosimilars market, with a focus on microbiome-based products. The company’s commitment to innovation and sustainability has helped it carve out a niche in the competitive biosimilars industry.
9. Glenmark Pharmaceuticals Ltd.
– Market Share: 3%
– Glenmark Pharmaceuticals Ltd. is gaining momentum in the biosimilars market, particularly in the microbiome-based segment. The company’s strong R&D pipeline and global presence make it a top contender in the Indian biosimilars industry.
10. Aurobindo Pharma Ltd.
– Market Share: 2%
– Aurobindo Pharma Ltd. is an emerging player in the biosimilars market, with a growing focus on microbiome-based products. The company’s strategic investments in R&D and manufacturing capabilities position it for future growth in 2026.
Insights:
The Indian biosimilars market is poised for significant growth in 2026, driven by factors such as increasing demand for affordable biologic drugs and a favorable regulatory environment. Companies that focus on microbiome-based products are expected to lead the market, with Biocon Ltd., Dr. Reddy’s Laboratories Ltd., and Cadila Healthcare Ltd. emerging as key players. With a projected market size of $2.7 billion by 2026, the Indian biosimilars industry presents lucrative opportunities for both domestic and international companies looking to capitalize on this growing market.
Related Analysis: View Previous Industry Report
